Leveraging Behavioral Science to Improve Medicine Optimization Conversations With Older Adults

NCT ID: NCT06698770

Last Updated: 2025-09-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

2420 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-11-01

Study Completion Date

2025-01-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Our online, survey-based experiment will include 2,400 adults who are 65-years and older (n=1,200 each from United States and Australia). Each participant will be asked to give their opinions on a hypothetical patient scenario that has been developed by our diverse team in partnership with our stakeholder organizations.This work is expected to significantly contribute to our understanding of how older adults make decisions about deprescribing medications.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Deprescribing

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Start medication - Lower chance of future health problems

Participants read a hypothetical scenario where a doctor recommends starting a new medication to lower their chances of experiencing significant health problems.

Group Type EXPERIMENTAL

Anticipated long-term use of medication

Intervention Type OTHER

In this hypothetical scenario, the doctor anticipates that the participant will take this medication for the rest of their life.

Period re-evaluation of medication

Intervention Type OTHER

In this hypothetical scenario, the doctor anticipates that the participant will take this medication for the rest of their life but will periodically re-evaluate the benefits and risks of the medication.

Start medication - Higher risk without medication

Participants read a hypothetical scenario where a doctor recommends starting a new medication because they could experience a higher risk of serious health problems without it

Group Type EXPERIMENTAL

Anticipated long-term use of medication

Intervention Type OTHER

In this hypothetical scenario, the doctor anticipates that the participant will take this medication for the rest of their life.

Period re-evaluation of medication

Intervention Type OTHER

In this hypothetical scenario, the doctor anticipates that the participant will take this medication for the rest of their life but will periodically re-evaluate the benefits and risks of the medication.

Stop medication - Lack of benefit

Participants read a hypothetical scenario where a doctor suggests stopping the medication due to a lack of benefit.

Group Type EXPERIMENTAL

Anticipated long-term use of medication

Intervention Type OTHER

In this hypothetical scenario, the doctor anticipates that the participant will take this medication for the rest of their life.

Period re-evaluation of medication

Intervention Type OTHER

In this hypothetical scenario, the doctor anticipates that the participant will take this medication for the rest of their life but will periodically re-evaluate the benefits and risks of the medication.

Stop medication - Potential for harm

Participants read a hypothetical scenario where a doctor suggests stopping the medication due to the potential for harm.

Group Type EXPERIMENTAL

Anticipated long-term use of medication

Intervention Type OTHER

In this hypothetical scenario, the doctor anticipates that the participant will take this medication for the rest of their life.

Period re-evaluation of medication

Intervention Type OTHER

In this hypothetical scenario, the doctor anticipates that the participant will take this medication for the rest of their life but will periodically re-evaluate the benefits and risks of the medication.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Anticipated long-term use of medication

In this hypothetical scenario, the doctor anticipates that the participant will take this medication for the rest of their life.

Intervention Type OTHER

Period re-evaluation of medication

In this hypothetical scenario, the doctor anticipates that the participant will take this medication for the rest of their life but will periodically re-evaluate the benefits and risks of the medication.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 65 years and older and resides in Australia or the United States
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Sydney

OTHER

Sponsor Role collaborator

University of Michigan

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Vordenberg

Clinical Associate Professor of Clinical Pharmacy and Associate Chair, Clinical Pharmacy, College of Pharmacy

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Michigan

Ann Arbor, Michigan, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HUM00259517

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Medication Use and Quality of Life Among Older People
NCT05123313 ACTIVE_NOT_RECRUITING NA